Psyomics
Company Bio
Psyomics began as a Cambridge University spin-out and has developed a platform designed to capture comprehensive patient information, supporting intake, triage, and assessment within adult mental and behavioral health services. The platform operates at the referral-to-assessment stage, streamlining patient flow by reducing the need for patients to repeat their story, improving administrative efficiency, reducing clinical variation, and enabling multiple referral routes into a single point of access. Using a biopsychosocial model, it captures self-reported information from users in a structured and consistent manner, supporting clinicians' assessments of symptom profiles and levels of need.
Currently available in adult services, the platform is used in both the private sector (Priory) and the NHS, covering approximately 1 in 10 of the UK adult population. It is now being expanded to support Children and Young People (CYP) and Neurodevelopmental pathways, with the CYP launch scheduled for September 2025. Additionally, Psyomics has developed a biomarker using a dry blood spot test to aid in diagnosing Bipolar Disorder, which is expected to be available in 2026.
